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Vascular calcification, which contributes to cardiovascular
disease in patients with uremic hyperphosphatemia, is
associated with vascular cell expression of osteogenic genes,
including bone morphogenetic protein (BMP)-2 and
osteopontin (OPN). High inorganic phosphate levels in vitro
stimulate the osteogenic conversion of smooth muscle cells;
however, the mechanism governing this is not clear. We
found that high-phosphate medium increased the expression
of BMP-2 and OPN in mouse smooth muscle cells in culture.
However, this effect was lost in the presence of the
mineralization inhibitor, pyrophosphate, suggesting a
contribution of calcium phosphate crystals. Addition of
1–2mmol/l phosphate alone to growth medium was
sufficient to induce nanosized crystals after 1 day at 37 1C.
Isolated crystals were about 160nm in diameter and had a
calcium to phosphate ratio of 1.35, consistent with the
hydroxyapatite precursor octacalcium phosphate.
Nanocrystal formation increased fourfold in the absence of
serum, was blocked by fetuin-A, and was dependent on time
and on the concentrations of phosphate and calcium.
Purified synthetic hydroxyapatite nanocrystals and isolated
high-phosphate-induced nanocrystals, but not nanocrystal-
free high-phosphate medium, also induced BMP-2 and OPN.
Thus, our results suggest that BMP-2 and OPN are induced by
calcium phosphate nanocrystals, rather than soluble
phosphate. This mechanism may contribute, in part, to
hyperphosphatemia-related vascular cell differentiation
and calcification.
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Vascular calcification is now recognized as a significant factor
in cardiovascular diseases.1–3 It manifests as hydroxyapatite
deposition and, to varying degrees, the ectopic development
of bone and/or cartilage-like tissue.4,5 Vascular calcification
may occur within atherosclerotic plaque, where it may
regulate plaque stability,6,7 in cardiac valves,8,9 where it
impairs cardiac output, and in the medial layer of large
arteries, wherein it contributes significantly to cardiovascular
morbidity associated with both diabetes and chronic kidney
disease.3 Vascular calcification is primarily associated with
smooth muscle cells (SMCs) and their progenitors, both of
which undergo osteogenic differentiation and calcification
in vitro, and which are used as in vitro models of vascular
calcification.8,10–12
The clinical condition associated with most severe vascular
calcification is end-stage renal disease, in which evidence
points to inorganic phosphate (Pi) and its inhibitor,
pyrophosphate (PPi), as central regulators.12,13 End-stage
renal disease patients are often hyperphosphatemic, defined
as a phosphate concentration of 2mmol/l, compared with
1–1.5mmol/l in healthy patients.2,12 In mice, serum phos-
phate is higher at baseline (B2.6mmol/l) and surgically
induced chronic kidney disease can result in Pi levels as high
as B3.5mmol/l.14 In vitro studies and animal models of
vascular calcification suggest that Pi not only participates in
hydroxyapatite crystal formation, but also directly induces
osteogenic gene expression when applied at concentrations
similar to those in hyperphosphatemic subjects in vivo.12,14–16
Li et al.12 showed that the effects of high Pi on core-binding-
factor a1 (Cbfa1/Runx2) and osteocalcin in human SMCs are
mediated by Pi import through the sodium-dependent
phosphate co-transporter Pit-1, as demonstrated by Pit-1
small interfering RNA knockdown. However, some studies
have attributed the effects of high Pi, such as osteopontin
(OPN) induction,17,18 to Pit-1, based on the use of
phosphonoformic acid (PFA) as a specific inhibitor of
phosphate transport. However, PFA, an analog of PPi, is a
more potent inhibitor of calcium crystal formation than of
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Pit-1.19 Interestingly, micro- or nanoscale hydroxyapatite and
other calcium phosphate crystals may also have the ability to
regulate cell phenotype.6,20,21 In this study, we investigated
the mechanism(s) by which increased concentrations of Pi
may regulate osteogenic gene expression in mouse aortic
SMCs (MASMCs) and demonstrate that calcium phosphate
nanocrystals, formed in the presence of high Pi, may regulate
gene expression independently of free Pi.
RESULTS
High levels of Pi induce calcification and osteogenic gene
expression in MASMCs
Vascular calcification is modeled in vitro by treating SMCs
with high-Pi medium (2–4mmol/l Pi),14,19,22 corresponding
to hyperphosphatemic concentrations. This approach is
an alternative to supplementation with organic phosphate
(b-glycerophosphate; 5–10mmol/l), a standard addition to
medium for bone cell culture. MASMCs were incubated in
control medium (10% of fetal bovine serum–a modified
Eagle’s medium (FBS–aMEM); B1mmol/l Pi) or high-Pi
medium (additional 2mmol/l Pi) for 7 days. High-Pi-
medium induced calcification in MASMC cultures in a
diffuse pattern, as detected by staining with von Kossa
(Figure 1a) and Alizarin red (Figure 1b). Quantitative assays
of calcium deposition at 7 or 14 days with Pi supplementa-
tion (0.5–2mmol/l) showed that Pi supplementation in
excess of 1mmol/l increased calcification (Figure 1c). To
determine whether MASMCs undergo osteogenic differentia-
tion in response to high Pi, we tested the effects of high Pi on
the expression of osteogenic differentiation factor, bone
morphogenetic factor-2 (BMP-2), and its inhibitor, matrix
gamma carboxyglutamic acid (GLA) protein, the osteogenic
transcription factors, Cbfa1 and osterix, and the mineraliza-
tion regulators, alkaline phosphatase (ALP; tissue-non-
specific isoform) and OPN. As the sodium-dependent Pi
transporter, Pit-1, has been implicated as an upstream
regulator of calcification in human SMCs,12 we also tested
its response to high-Pi medium in mouse SMCs. Gene
expression was quantified by real-time PCR using RNA from
MASMCs incubated in control or high-Pi medium for 24 h
or 7 days (Figure 2a). High Pi significantly induced BMP-2
and OPN expression at 24 h but had no effect on the other
genes, although there was a trend toward increased osterix
expression (P¼ 0.08). After 7 days, the BMP-2 induction was
even more pronounced, whereas OPN was induced by a
similar level at 24 h and 7 days. At 7 days, high Pi significantly
induced osterix and Pit-1, whereas matrix GLA protein
expression was significantly downregulated. High Pi signifi-
cantly increased OPN protein levels after 7 days compared
with control, as determined by western blotting (Figure 2b).
BMP-2 protein levels, detected by enzyme-linked immuno-
sorbent assay, were also increased in the conditioned medium
of MASMC treated for 7 days with high Pi (48.2±7.3 pg/ml
compared with 8.4±5.9 pg/ml in controls).
Pi-induced MASMC calcification is ALP independent
ALP, an important marker of osteogenic differentiation,
permits calcification through the removal of inhibitory PPi
or, when b-glycerophosphate is used in the culture medium,
through increased extracellular Pi concentration. After 7 days
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Figure 1 |High inorganic phosphate (Pi) dose dependently induces calcification in mouse aortic smooth muscle cell (MASMC)
cultures. (a) Von Kossa staining of MASMCs treated for 7 days with control or high-Pi medium. Bar¼ 100 mm. (b) Alizarin red staining of
MASMCs treated for 7 days with control or high-Pi medium. (c) Calcium deposition normalized to total protein after 7 or 14 days with
control or high-Pi (0.5–2mmol/l) medium. *Po0.05 versus control (0).
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of treatment, high Pi significantly inhibited ALP activity
levels in MASMCs compared with the control medium
(Figure 2c). This suggests that ALP is unnecessary for
Pi-induced calcification of MASMCs. Indeed, ALP inhibition
with levamisole (100 mM) failed to attenuate high-Pi-induced
calcification (Figure 2d).
PPi prevents Pi-induced expression of BMP-2 and OPN
To test the hypothesis that, similar to PFA, PPi might regulate
high Pi induction of gene expression, we tested the effects of
PPi on gene expression in cells treated with high-Pi medium.
As BMP-2 and OPN were significantly induced by high Pi
at 24 h, we chose to focus on these genes and this time
point in subsequent gene expression experiments. MASMCs
were treated for 24 h with high Pi and/or PPi (10 mM). The
induction of BMP-2 and OPN by high Pi was completely
blocked by co-treatment with PPi, which alone had no effect
on expression of either gene (Figure 3a and b).
Characterization of high-Pi-induced calcium deposition
As a major extracellular function of PPi is inhibition of
calcium crystal formation,13,23,24 we tested whether its inhibi-
tory effect on high-Pi-induced gene expression was because
of its inhibition of calcium phosphate crystals themselves. To
determine whether crystals were forming independently of
cells, we quantified calcium deposition in the presence or
absence of cells in wells 7 days after incubation with control
or high-Pi (additional 1 or 2mmol/l) medium. In the
presence of cells, calcium deposition increased 27-fold with
2mmol/l added (high) Pi medium (Figure 3c). Importantly,
the same level and fold increase occurred in the absence of
cells. Indeed, with 1mmol/l high-Pi medium, results showed
significantly more calcium deposition in the absence of cells
(Figure 3c), suggesting that the cells inhibited calcium
deposition in this situation. The high-Pi medium had similar
effects on calcium deposition in cultures of human
embryonic kidney-293 cells (Figure 3d), which are not
known to undergo osteogenic differentiation. The induction
of calcium deposits by high-Pi medium was robust,
irrespective of pH of the Pi stock solution (pH 4.3, 7.4, or
8.3), presence or absence of cells, type of medium (Dulbecco’s
modified Eagle’s medium versus aMEM), type of cell, size of
culture wells (6-, 12-, 48-well plates), or whether the wells
had been pre-incubated with control medium (data not
shown).
Significant, cell-free calcium deposition was detectable
after 24 h, with 2mmol/l high-Pi medium, and after 3 days,
with 1mmol/l Pi; it increased significantly by 7 days with
both doses (Figure 4a). The effect of high-Pi medium on
calcium deposition was also modulated by serum calcium
concentration and PPi treatment, assessed after 3 days.
Importantly, calcium deposition was completely prevented by
PPi (10–100 mM; Figure 4b). As previously shown,25 the
absence of serum (FBS) significantly increased calcium
deposition fourfold in high-Pi medium compared with
10% of FBS (Figure 4c). The inhibitory effect of serum on
crystal formation may be primarily because of the serum
protein fetuin-A.26,27 In this study, the addition of fetuin-A
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Figure 2 |High inorganic phosphate (Pi) induces osteogenic gene expression but not alkaline phosphatase (ALP) activity. (a) Effect
of high-Pi medium on the expression of bone morphogenetic protein-2 (BMP-2), osteopontin (OPN), osterix (Osx), Pit-1, core-binding-factor
a1 (Cbfa1), ALP, and matrix GLA protein (MGP) after 24 h or 7 days. Expression levels were normalized to b-actin and expressed relative
to control medium (1; dotted line). (b) Effect of high-Pi medium on OPN protein levels in mouse aortic smooth muscle cells (MASMCs)
after 7 days determined by western blotting. Tubulin was used as a loading control. (c) Total ALP activity of MASMCs treated for 7 days
with control or high-Pi medium (representative experiment). (d) Calcium deposition in MASMCs treated as in c with or without levamisole
(leva; 100mM). *Po0.001; #Po0.01; zPo0.05 versus control. GLA, gamma carboxyglutamic acid.
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(10 mM) completely inhibited calcium deposition in serum-
free medium but had no additional inhibitory effect in the
presence of FBS, which contains 100–200 mM fetuin-A28
(Figure 4c). Reducing the medium Ca concentration from
1.8mmol/l (control) to 1.2 or 0.6mmol/l prevented high-Pi-
induced calcium deposition (Figure 4d).
To further characterize these deposits, we isolated them by
centrifugation (see Materials and Methods) from high-Pi
medium after 3 days at 37 1C. Scanning electron microscopic
and electron dispersive spectroscopic analysis of crystals, as
shown in Figure 5a, determined that the crystals had a
Ca:P ratio of 1.36±0.013, identifying them as octacalcium
phosphate (Ca8(HPO4)2(PO4)4  5H2O), a precursor of hy-
droxyapatite. Further analysis of crystal size by atomic force
microscopy (Figure 5b) identified that the crystals varied in
diameter from 30 to 500 nm (mean 161±13 nm, n¼ 46) and
had an aspect ratio of 2.6±0.1. Therefore, in this report, we
subsequently use the term nanocrystals to refer to these high-
Pi-induced crystals.
High-Pi-induced nanocrystals, rather than free Pi, enhance
BMP-2 and OPN expression in MASMCs
To compare the relative effects of free Pi versus Pi-induced
nanocrystals on gene expression, we isolated nanocrystals
from high-Pi medium by centrifugation and resuspended
them in the control medium for comparison with the
supernatant. Pellets (nanocrystals) centrifuged from 1ml of
high-Pi medium contained 21±1.6 mg (0.53±0.11 mmol)
calcium and 0.30±0.01 mmol Pi (Table 1). This led to a 0.5
and 0.3mmol/l reduction in medium Ca and Pi concentra-
tion of the supernatant, respectively (Table 1). The control
supernatant Ca and Pi concentration was not significantly
affected, and the high-Pi pellet did not redissolve after
resuspension in the control medium, as similar levels of pellet
calcium and phosphate were recovered after recentrifugation
(Table 1). The high-Pi pellet resuspension significantly in-
duced both BMP-2 and OPN compared with control medium,
whereas the high-Pi supernatant did not (Figure 6a and b).
Synthetic nanocrystals induce BMP-2 and OPN
To further test whether the induction of gene expression is
attributable to nanocrystals, we used synthetic hydroxyapatite
nanocrystals o200 nm in diameter, the size range of the
nanocrystals induced by high Pi. By assuming the Mw and
formula of high-Pi-induced nanocrystals to be octacalcium
phosphate, in the experiments with resuspended high-Pi
nanocrystal pellets, we used crystals concentrations of
B30 mg/ml. Previous investigators have used concentrations
of 100–200 mg/ml.6,29 Synthetic hydroxyapatite nanocrystals
(10–200 mg/ml) dose-dependently induced expression of
BMP-2 and OPN in MASMCs at 24 h (Figure 6c and d),
with 25 mg/ml being the lowest dose at which a significant
effect was observed. Consistent with the effect of high Pi
(Figure 2a), the synthetic hydroxyapatite nanocrystals caused
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Figure 3 |Pyrophosphate (PPi) prevents high-inorganic phosphate (Pi)-induced early gene expression. (a, b) Effect of high-Pi medium
with or without PPi (10 mM) on expression of bone morphogenetic protein-2 (BMP-2; a) and osteopontin (OPN; b) after 24 h (normalized
to b-actin). *Po0.001 versus control; #Po0.001 versus Pi alone. (c, d) Calcium deposition after 7 days with control, 1, or 2mmol/l Pi
medium in the absence of cells or with mouse aortic smooth muscle cells (MASMCs; c; representative experiment) or human embryonic
kidney-293 (HEK-293) cells (d). *Po0.05 versus controlþ cells; #Po0.05 versus 1mmol/lþ cells.
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Figure 4 |Regulation of calcium deposition in high-inorganic phosphate (Pi) medium. (a) Cell-free nanocrystal formation (calcium
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Figure 5 |Characterization of high-inorganic phosphate (Pi)-induced nanocrystals. (a) Scanning electron microscopy of
nanocrystals isolated from high-Pi medium after 3 days. (b) Atomic force microscopy of a representative nanocrystal isolated from
high-Pi medium after 3 days.
Table 1 | Phosphate and calcium levels in medium and nanocrystal pellets
Day 3, medium Day 3, pellet resuspensiona
Day 0, medium (mmol/l) Supernatant (mmol/l) Pellet (lmol) Supernatanta (mmol/l) Pelleta (lmol)
Phosphate
Control 0.97±0.02 0.96±0.03 0.01±0.002 0.99±0.02 0.02±0.003
High Pi 3.06±0.02 2.72±0.09 0.30±0.014 0.92±0.06 0.31±0.019
Calcium
Control 2.27±0.04 2.24±0.09 0.02±0.002 2.19±0.04 0.01±0.001
High Pi 2.27±0.01 1.71±0.06 0.53±0.040 2.26±0.05 0.51±0.007
aAfter centrifugation, day 3 pellets were resuspended in fresh control medium then recentrifuged.
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a greater induction of BMP-2 than that of OPN (Figure 6c
and d).
DISCUSSION
Hyperphosphatemia is closely associated with vascular
calcification, and elevated levels of Pi in cultured SMCs
induce osteogenic genes. In this study, we describe the
novel finding that calcium phosphate nanocrystals induce the
expression of BMP-2 and OPN, genes associated with
vascular calcification in vitro and in vivo.15,30
BMP-2 is a potent pro-osteogenic factor consistently
associated with vascular calcification, which is expressed by
both endothelial cells and SMCs.31 OPN deficiency in mouse
SMCs in vitro promotes calcium deposition,22 but OPN has
multiple functions, and probably multiple roles, in athero-
sclerosis and vascular calcification in vivo.32 Importantly, a
key osteoblast regulatory factor, ALP, is not induced by high-
Pi medium in these MASMCs (Figure 2a and b). The lack of
ALP induction by high Pi was previously observed by others
in SMCs and osteoblasts.13,24 Our finding that high-Pi
medium induces expression of osterix, but not Cbfa1, is
consistent with results of Mathew et al.14 and Prosdocimo
et al.24 and suggests that high Pi is not sufficient to induce the
full spectrum of osteogenic differentiation. In immortalized
human SMC, Li et al.12 found Cbfa1 induction by high levels
of Pi and its inhibition by knockdown of the Pi transporter
Pit-1. Species differences and/or immortalization may
explain this difference.
We set out to develop a murine cell model of high-Pi-
induced vascular calcification. Following the protocols of
previous studies, we observed a diffuse pattern of calcium
deposition as described by others.12,14,24 Interestingly, we
found similar levels of calcium deposition from high-Pi
medium in the absence of cells, suggesting that it was not cell
dependent. Indeed, calcification was actually inhibited by
cells in the medium with 1mmol/l excess Pi (Figure 3c), an
effect that may be explained by a recent study showing that
high-Pi medium transiently increases extracellular PPi.24 Our
finding of cell-independent calcium deposition with 1mmol/l
excess Pi is consistent with those of Yang et al.33 and Young
et al.27 showing crystalline calcium phosphate deposition in
medium or serum with 1–1.3mmol/l excess Pi. It also fits
with those of Reynolds et al.,34 which shows that the presence
or absence of SMCs did not affect the degree of calcification
in serum-free high-Ca/Pi medium. Young et al.27 derived
crystalline particles from Pi-supplemented serum-containing
medium that consisted of colloids of hydroxyapatite mineral,
albumin, and fetuin-A, an abundant serum protein that
forms colloids with nascent calcium phosphate crystals,
preventing further growth (Figure 5b; Heiss et al.26).
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Figure 6 |Calcium phosphate nanocrystals, not free inorganic phosphate (Pi), induce bone morphogenetic protein-2 (BMP-2)
and osteopontin (OPN) in mouse aortic smooth muscle cells. (a, b) Effect of control (Con) or high-Pi medium supernatants or pellet
resuspensions (nanocrystals) on expression of BMP-2 (a) and OPN (b; normalized to b-actin) after 24 h. *Po0.001 versus control pellet
resuspension. (c, d) Effect of 10–200 mg/ml synthetic hydroxyapatite nanocrystals on the expression of BMP-2 (c) and OPN (d; normalized to
b-actin) after 24 h. *Po0.001; #Po0.01; zPo0.05 versus control. HA, hydroxyapatite.
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Although the nanocrystals in our experiments may also be
associated with serum proteins, such as fetuin-A, these
proteins seem to be unnecessary for gene induction, as
synthetic hydroxyapatite nanocrystals also had gene induc-
tion activity (Figure 6c and d).
We demonstrate that high-Pi-induced nanocrystals,
rather than free Pi itself, may be the active factor that
induces BMP-2 and OPN in MASMCs, as high-Pi-induced
gene expression was prevented by the crystallization
inhibitor PPi. Although we cannot exclude the possibility
that PPi blocks the effect of free Pi on gene induction, to our
knowledge, there is no precedent for such a phenomenon.
Furthermore, at a much higher concentration (500 mM),
PPi actually induces OPN expression.23 In support of our
findings, the PPi analog, PFA, is known to block the
induction of OPN by high-Pi medium.17,18 PFA has been
used as an inhibitor of Pit-1; however its effects on
calcification have been attributed to its direct inhibition of
calcium crystal formation.19
Our in vitro findings suggest a potential role for
nanocrystals in vivo. Nanocrystals are present within human
calcification,6,35 consisting of hydroxyapatite, carbonate-
substituted hydroxyapatite, and/or amorphous calcium
phosphate.6,36 Nanocrystals may potentially arise, under
permissive conditions, from circulating fetuin–mineral com-
plexes,26,27 which are found at high levels in rat serum under
conditions that cause medial calcification.37 Whether nano-
crystals are present before osteochondrogenic changes in vivo
is currently unknown. A number of studies show that
osteochondrogenic gene expression seems to precede light
microscopic evidence of matrix calcification.15,38–40 However,
nanocrystals may precede microscopic matrix mineralization,
and Neven et al.41 recently observed that both increased
chondrogenic genes and calcification appear at the same time
in uremic rats. More sensitive techniques that detect
nanocrystals in the artery wall42 may be required to answer
this important question.
Nanocrystals have pleiotropic effects, including the
induction of inflammatory cytokines in macrophages,21
mitogenesis and matrix metalloproteinases in osteoblasts20
and fibroblasts,29 autophagy,43 and, under serum-free con-
ditions, the induction of apoptosis in SMCs.6 Cheung and
coworkers29 showed that nanocrystals were endocytosed, and
our preliminary results also suggest these nanocrystals are
endocytosed (data not shown). However, the molecular
mechanism or pathway by which these nanocrystals act on
gene expression remains to be elucidated. Ewence et al.6
showed that endocytosed nanocrystals were dissolved within
lysosomes, causing a cytoplasmic calcium burst leading to
apoptosis. It is also possible that nanocrystals directly affect
DNA transcription complexes, as they have been reported to
enter the nucleus and interact with histones.44 Nevertheless,
our findings support the view proposed by Shanahan45 that
vascular calcium crystals are far from inert and may promote
the pro-inflammatory, pro-osteogenic environment asso-
ciated with vascular calcification.
In summary, we have found that calcium phosphate
nanocrystals regulate gene expression of SMCs in vitro. This
adds a further dimension to the already complex network of
interactions between the inflammatory cytokines, growth
factors, hormones, matrix proteins, enzymes, and mineral
ions that regulate vascular calcification in vivo.
MATERIALS AND METHODS
Cell culture
A primary cell line of MASMCs was cultured as previously
described46 in 10% FBS–aMEM (Mediatech, Manassas, VA) and
used at passages 6–8. Major experiments were replicated with similar
results in two independent MASMC lines (data not shown). Human
embryonic kidney-293 cells were cultured in 10% FBS–aMEM. For
calcification and ALP assays, cells in 48-well plates (10,000 cells/cm2)
were treated for the indicated times starting from 24 h after plating;
in RNA experiments, MASMCs were plated in 6- or 12-well plates
and treated for 24 h or 7 days, starting from 48 h after plating. When
indicated, the media Pi concentration was increased using 0.5mol/l
sodium phosphate, pH 7.4 (a mixture of NaH2PO4 and Na2HPO4).
Basal 10% FBS–aMEM medium contains B1.0mmol/l Pi. Unless
otherwise stated in the results, ‘high-Pi’ medium refers to a medium
with an additional 2mmol/l Pi (B3mmol/l final). In experiments in
which Ca concentration was varied calcium-free Dulbecco’s
modified Eagle’s medium (HyClone/ThermoFisher, Logan, UT)
with added calcium chloride and 10% FBS was used. Levamisole and
synthetic hydroxyapatite nanocrystals (o200 nm in diameter) were
obtained from Sigma (St Louis, MO). Synthetic nanocrystals
suspended in culture medium were sonicated before treatment of
cells. Images of cells were acquired using an Olympus CKX41
microscope (Olympus, Center Valley, PA) and adjusted to the same
extent for brightness and contrast using ImageJ software (NIH,
Bethesda, MD).
ALP activity assay
ALP activity was assessed in quintuplicate colorimetrically using
p-nitrophenol as substrate. Cells in 48-well plates were washed with
phosphate-buffered saline, lysed in 100ml lysis buffer (1mmol/l
MgCl2, 0.2% Igepal CA-630; Sigma), and sonicated. Enzyme activity
(sigma units; mmol p-nitrophenol/h) was determined using
p-nitrophenol phosphate (Sigma) as substrate. Values were normal-
ized to total protein levels, as assessed by the Bradford method
(Bio-Rad, Hercules, CA).
Calcium and phosphate assays
Calcium deposition was quantified by the o-cresolphthalein method
as previously described.46 In experiments analyzing cell-free
deposition, all the wells (with and without cells) were not washed
with phosphate-buffered saline between removal of culture medium
and addition of 0.6mol/l HCl, as in the absence of cells calcium
deposits did not adhere to the culture dish. Phosphate was
quantified using a Malachite Green phosphate assay kit according
to the manufacturer’s protocol (Biochain, Hayward, CA). Calcifica-
tion was visualized by von Kossa or Alizarin red staining as
previously described.30
RNA isolation and real-time PCR
Total RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA) and
one-step reverse transcriptase-quantitative PCR (Biochain) performed
using gene-specific primers (Table 2) as previously described.46
420 Kidney International (2011) 79, 414–422
or ig ina l a r t i c l e AP Sage et al.: Nanocrystals induce BMP-2 and OPN in SMCs
Western blotting and enzyme-linked immunosorbent assay
Whole-cell lysates were prepared using lysis buffer supplemented
with phosphatase and protease inhibitors, and western analysis was
performed using standard protocols using antibodies against mouse
OPN (R&D Systems, Minneapolis, MN) and a/b-tubulin (Cell
Signaling, Danvers, MA). BMP-2 in MASMC conditioned medium
was detected by enzyme-linked immunosorbent assay according to
the manufacturer’s instructions (R&D Systems).
Treatment of cells with calcium phosphate nanocrystals
Control or high-Pi medium (1ml) was incubated at 37 1C for 3 days
and then centrifuged at 16,000 g for 1 h.27 The pellets (nanocrys-
tals), resuspended in 1ml fresh control medium (pellet resuspen-
sions), and the supernatants were then each used to treat cells and
RNA extracted after 24 h. Alternatively, pellets dissolved in 0.6mol/l
HCl and supernatants diluted with water were analyzed for calcium
and phosphate concentrations.
Scanning electron microscopy, energy-dispersive
spectroscopy, and atomic force microscopy
High-Pi medium (1ml) was incubated at 37 1C for 3 days, then
centrifuged at 16,000 g for 1 h. Pellets were washed with H2O, then
recentrifuged. For scanning electron microscopy and electron-
dispersive spectroscopy, the pellets were dried, transferred onto
carbon tape, and coated with gold (5 nm) before imaging using a
JEOL JSM-6700F (JEOL, Tokyo, Japan); the Ca:P ratio was
determined with on-board energy dispersive spectroscopy and
EDAX Genesis software (Ametek, NJ). For atomic force microscopy,
the pellets were resuspended in H2O and transferred onto mica
disks, then dried with nitrogen gas. Samples were scanned in tapping
mode using a Veeco Bioscope II and RTESP cantilever (Veeco, Santa
Barbara, CA). Data were analyzed using SPIP software (version 4.8,
Nanoscience Instruments, Phoenix, AR).
Statistical analysis
All experiments were performed in at least triplicate per treatment
and repeated in three independent experiments. Results are
presented as the mean±s.e.m. of data from three experiments
combined unless otherwise stated. Data were analyzed by unpaired
t-test (between two groups) or one-way analysis of varaince with
Tukey or Dunnett post-test analysis (for three or more groups) using
Graphpad Prism software (San Diego, CA); a P value of o0.05 was
considered significant.
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